20 20 vision in IBD

Learning objective

After this meeting, participants should be able to:

• Describe the pathways that can be a therapeutic target in inflammatory bowel disease (IBD)
• Discuss recent data in IBD and consider the impact of targeting the IL-12/23 pathway in Crohn's disease (CD)
• Consider how treat-to-target strategies may be applied to optimize personalized disease management
• Reflect on how the use of drugs targeting the IL-12/23 pathways is evolving for the treatment of patients with CD in the real world

Speakers:

Raja Atreya (Scientific Committee), Subrata Ghosh (Scientific Committee), and Axel Dignass